2023-06-29 08:55:00
The US Food and Drug Administration (FDA) has approved the first donor cell therapy for type 1 diabetes. Donislecel, under the trade name Lantidra, is pancreatic beta cells obtained from deceased people. The main mechanism of action of the drug is considered to be the secretion of insulin by the introduced allogeneic beta cells – in some patients, for a long period, the need for constant insulin administration to correct glucose levels disappears. Approval Message placed on the website of the department.
This therapy is designed primarily for adult patients who cannot reach the target level of glycated hemoglobin due to recurring episodes of severe hypoglycemia – an excessive decrease in blood glucose. Cells are injected once into the portal vein, depending on the patient’s response, additional infusion is possible. In two non-randomized studies, following infusion, 21 people did not need insulin for a year, and ten people did not need insulin for more than five years.
1688125508
#FDA #approves #beta #cell #transplant #diabetes #treatment
